Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer
Authors:
- 1 March 2021
- journal article
- review article
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 109 (4) , 953-963
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- National Institutes of Health (LRP 1 L30 CA231572-01)
- Varian Medical Systems
- American Cancer Society (CSDG-CCE 133738)
- Janssen Pharmaceutica
- Bayer Fund
- ViewRay
- Astellas Pharma US
This publication has 63 references indexed in Scilit:
- Randomized Noninferiority Trial of Reduced High-Dose Volume Versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Use of Potentially Curative Therapies for Muscle-invasive Bladder Cancer in the United States: Results from the National Cancer Data BaseEuropean Urology, 2013
- Phase I study of radiochemotherapy with gemcitabine in invasive bladder cancerRadiotherapy and Oncology, 2011
- International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 TrialJournal of Clinical Oncology, 2011
- Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancerCancer, 2010
- LIFE AND DEATH OF SPARE (SELECTIVE BLADDER PRESERVATION AGAINST RADICAL EXCISION): REFLECTIONS ON WHY THE SPARE TRIAL CLOSEDBJU International, 2010
- Bladder‐sparing, combined‐modality approach for muscle‐invasive bladder cancerCancer, 2007
- Cystectomy for Transitional Cell Carcinoma of the Bladder: Results of a Surgery Only Series in the Neobladder EraJournal of Urology, 2006
- Combined-Modality Therapy With Gemcitabine and Radiotherapy As a Bladder Preservation Strategy: Results of a Phase I TrialJournal of Clinical Oncology, 2004
- Neoadjuvant Cisplatinum Based Combination Chemotherapy in Patients with Invasive Bladder Cancer: A Combined Analysis of Two Nordic StudiesEuropean Urology, 2004